Technology | October 21, 2011

FDA Clears Segasist Prostate Auto-Contouring Treatment Planning Software

October 21, 2011 — Segasist Technologies, a Canadian software company, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its prostate auto-contouring software Segasist P-AC. 

The software is a tool developed for the purpose of segmenting magnetic resonance (MR), computed tomography (CT) and ultrasound images of the prostate gland for diagnostic and treatment-planning purposes. It can be trained by individual clinicians to accurately and quickly process prostate images, including fast slice-by-slice auto-contouring and volumetric calculations.

It was externally validated at the London Health Sciences Centre (London, Ontario). Experts from the Sunnybrook Research Institute and Sunnybrook Health Sciences Centre (Toronto, Ontario) also participated in the validation process by providing input in the form of gold standard contours.

The current version of Segasist P-AC is a complete segmentation solution able to adjust the contouring process for prostate delineation in any modality. It can improve the segmentation result by adjusting its contouring techniques using images previously marked by the clinician. That gives the clinical expert the opportunity to use his own markings to train the software, even though the software can also be delivered pre-trained.

For more information: www.segasist.com

Related Content

Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
Varian Acquires Mobius Medical Systems
News | Quality Assurance (QA) | February 06, 2018
February 6, 2018 – Varian announced it has acquired privately-held Mobius Medical Systems, a...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
RayStation Selected for London's Charing Cross Hospital and Hammersmith Hospital
News | Treatment Planning | January 30, 2018
Imperial College Healthcare NHS Trust in London, U.K., has chosen RayStation as the sole treatment planning system for...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Overlay Init